点击上面“蓝字”关注我们!本文来源于深蓝观;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!临近年末,又到了MNC快速消耗年度BD预算,在全球各地买买买的季节。近来,作为交易重地的中国,也释放了不少利好消息。10月28日,荃信生物宣布与罗氏就自免双抗QX031N达成全球独家合作与许可协议。首付款7500万美元,总额可至多拿到9.95亿美元。要知道,QX031N只是一款临床前产品,这也让首付款和总...
Source Link点击上面“蓝字”关注我们!本文来源于深蓝观;如果喜欢,欢迎在文末处点个“在看”,感谢您的支持!临近年末,又到了MNC快速消耗年度BD预算,在全球各地买买买的季节。近来,作为交易重地的中国,也释放了不少利好消息。10月28日,荃信生物宣布与罗氏就自免双抗QX031N达成全球独家合作与许可协议。首付款7500万美元,总额可至多拿到9.95亿美元。要知道,QX031N只是一款临床前产品,这也让首付款和总...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.